Internal Medicine, Rheumatology · El Paso, TX
NPI
1225320278
Since 2011
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
3
Medicare group memberships
Hospitals
4
Hospital affiliations
4532 N Mesa St Ste 2a
El Paso, TX, 79912
Phone (915) 544-0326
Groups this clinician bills Medicare through
Medicare paid, 2024
$87K
2,762 services
Medicare patients, 2024
173
Average age 73
Drug cost, 2024
$12.5M
9,708 prescriptions
Company payments, 2025
$2,321
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Luis C Salayandia was code 99214 (office e&m - established), 297 times for 161 patients. In total Luis C Salayandia billed 2,762 services in 27 codes, and Medicare paid $87K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-08-07.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 297 | 161 | $89.14 | $26K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 210 | 22 | $0.80 | $167 |
| 20610 Joint Injection | Office | 29 | 19 | $51.53 | $1,494 |
| 96365 Intravenous Infusion, Hydration | Office | 24 | 11 | $46.63 | $1,119 |
| 99213 Office E&M - Established | Office | 13 | 11 | $63.76 | $829 |
By year: 2022 $111K for 3,787 services; 2023 $124K for 5,616 services; 2024 $87K for 2,762 services.
Medicare prescription drug claims, 2024
In 2024, the drug Luis C Salayandia prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 1,066 prescriptions and refills. In total Luis C Salayandia wrote 9,708 Medicare prescriptions that cost $12.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 1,066 | 2,522 | 346 | $43K |
| Prednisone Generic | 823 | 1,221 | 318 | $4,160 |
| Methotrexate Methotrexate Sodium | 696 | 1,647 | 240 | $14K |
| Humira(Cf) Pen Adalimumab | 450 | 468 | 56 | $3.6M |
| Tramadol Hcl Generic | 420 | 425 | 98 | $6,229 |
| Gabapentin Generic | 379 | 880 | 121 | $7,653 |
| Rinvoq Upadacitinib | 378 | 390 | 50 | $2.5M |
| Enbrel Sureclick Etanercept | 286 | 290 | 33 | $2.1M |
| Sulfasalazine Generic | 226 | 577 | 84 | $8,827 |
| Folic Acid Generic | 179 | 448 | 65 | $1,582 |
| Ibuprofen Generic | 176 | 243 | 61 | $3,105 |
| Cyclobenzaprine Hcl Generic | 175 | 280 | 54 | $2,106 |
| Pregabalin Generic | 175 | 216 | 43 | $3,246 |
| Leflunomide Generic | 171 | 399 | 61 | $8,057 |
| Sulfasalazine Dr Sulfasalazine | 146 | 275 | 51 | $5,170 |
Brand drugs: - claims; generic drugs: 7,405 claims; opioid claims: 540.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Luis C Salayandia $2,321 ($2,321 in general payments such as food, travel and fees) from 17 companies. The largest payer was Abbvie Inc. with $973.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 51 | $973 |
| Amgen Inc. AMGN | 24 | $383 |
| UCB, Inc. UCB.BR | 13 | $296 |
| E.R. Squibb & Sons, L.L.C. BMY | 5 | $108 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $91.06 |
| Madrigal Pharmaceuticals MDGL | 3 | $90.89 |
| Novartis Pharmaceuticals Corporation NVS | 3 | $85.1 |
| Genzyme Corporation SNY | 2 | $47.7 |
| GlaxoSmithKline, LLC. GSK | 3 | $47.28 |
| Pfizer Inc. PFE | 2 | $42.67 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.